Salvage radiotherapy after radical prostatectomy: analysis of toxicity by dose-fractionation in the RADICALS-RT trial
Authors
Petersen, P. M.Cook, A. D.
Sydes, M. R.
Clarke, Noel W
Cross, W.
Kynaston, H.
Logue, John P
Neville, P.
Payne, H.
Parmar, M. K.
Parulekar, W.
Persad, R.
Saad, F.
Stirling, A.
Parker, C. C.
Catton, C.
Affiliation
Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkIssue Date
2023
Metadata
Show full item recordAbstract
Purpose: Emerging data indicate comparable disease control and toxicity of normal postoperative fractionation and moderate hypofractionation radiation therapy (RT) in prostate cancer. In RADICALS-RT, patients were planned for treatment with either 66 Gy in 33 fractions (f) over 6.5 weeks or 52.5 Gy in 20 f over 4 weeks. This non-randomized, exploratory analysis explored the toxicity of these 2 schedules in patients who had adjuvant RT. Methods and materials: Information on RT dose was collected in all patients. The Radiation Therapy Oncology Group toxicity score was recorded every 4 months for 2 years, every 6 months until 5 years, then annually until 15 years. Patient-reported data were collected at baseline and at 1, 5, and 10 years using standard measures, including the Vaizey fecal incontinence score (bowel) and the International Continence Society Male Short-Form questionnaire (urinary incontinence). The highest event grade was recorded within the first 2 years and beyond 2 years and compared between treatment groups using the χ² test. Results: Of 634 patients, 217 (34%) were planned for 52.5 Gy/20f and 417 (66%) for 66 Gy/33f. In the first 2 years, grade 1 to 2 cystitis was reported more frequently among the 66 Gy/33f group (52.5 Gy/20f: 20% vs 66 Gy/33f: 30%; P = .04). After 2 years, grade 1 to 2 cystitis was reported in 16% in the 66-Gy group and 9% in the 52.5-Gy group (P = .08). Other toxic effects were similar in the 2 groups, and very few patients had any grade 3 to 4 toxic effects. Patients reported slightly higher urinary and fecal incontinence scores at 1 year than at baseline, but no clinically meaningful differences were reported between the 52.5 Gy/20f and 66 Gy/33f groups. Patient-reported health was similar at baseline and at 1 year and similar between the 52.5 Gy/20f and 66 Gy/33f groups. Conclusions: Severe toxic effects were rare after prostate bed radiation therapy with either 52.5 Gy/20f or 66 Gy/33f. Only modest differences were recorded in toxic effects or in patient-reported outcomes between these 2 schedules.Citation
Petersen PM, Cook AD, Sydes MR, Clarke N, Cross W, Kynaston H, et al. Salvage radiotherapy after radical prostatectomy: analysis of toxicity by dose-fractionation in the RADICALS-RT trial. International journal of radiation oncology, biology, physics. 2023 May 5. PubMed PMID: 37150260. Epub 2023/05/08. eng.Journal
International Journal of Radiation Oncology Biology PhysicsDOI
10.1016/j.ijrobp.2023.04.032PubMed ID
37150260Additional Links
https://dx.doi.org/10.1016/j.ijrobp.2023.04.032Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2023.04.032
Scopus Count
Collections
Related articles
- Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
- Authors: Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La Macchia M, Noris Chiorda B, Rancoita PM, Suardi N, Zerbetto F, Calandrino R, Montorsi F, Di Muzio N
- Issue date: 2014 Dec
- Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
- Authors: Beck M, Wust P, Barelkowski T, Kaul D, Thieme AH, Wecker S, Wlodarczyk W, Budach V, Ghadjar P
- Issue date: 2017 Aug 10
- Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
- Authors: Murgic J, Jaksic B, Prpic M, Kust D, Bahl A, Budanec M, Prgomet Secan A, Franco P, Kruljac I, Spajic B, Babic N, Kruslin B, Zovak M, Zubizarreta E, Rosenblatt E, Fröbe A
- Issue date: 2021 May 12
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
- Authors: Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P
- Issue date: 2019 Aug 3
- Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial.
- Authors: Qi X, Li HZ, Gao XS, Qin SB, Zhang M, Li XM, Li XY, Ma MW, Bai Y, Li XY, Wang D
- Issue date: 2020 Feb 1